Searched for
GENERIC INJECTABLE
Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 croreFosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak...- Large trade alert! Gland Pharma shares fall 3% after 1.2 crore shares change hands in 2 block deals; promoter Fosun likely sellerGland Pharma shares fell 3% after 1.22 crore shares changed hands in two block deals worth nearly Rs 5,818 crore. Promoter Fosun Pharma Ind...
- Block deal alert! Gland Pharma shares fall 3% as 1.2 crore shares change hands in 2 block deals; promoter Fosun likely sellerGland Pharma shares fell after a significant block deal involving Fosun Pharma Industrial. The company's VSEZ facility received zero USFDA ...
- Gland Pharma shares: Promoter Fosun Pharma likely to divest 5% equity worth Rs 2,279 crore via block dealFosun Pharma plans to divest 5% equity in Gland Pharma through a Rs 2,279.5 crore block deal at Rs 2,763 per share. Gland Pharma reported a...
- DRL, Emcure get approval to make breakthrough HIV drugIndia's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for l...
- Zydus Lifesciences gets USFDA nod for generic ascorbic acid injectionZydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in sp...
- Swadeshi 1.0 vs. Made in India 2.0: How India turned a 1905 boycott into a 2026 business strategyIndependence Day 2026: From the Swadeshi movement to Atmanirbhar Bharat. Early Swadeshi movements fostered indigenous industries against im...
- Jubilant Pharmova shares decline 6% after Q1 profits falls 45% YoYJubilant Pharmova shares fell after Q1 profit plunged 45% YoY to Rs 56 crore, despite revenue rising 17% to Rs 2,229 crore. The profit decl...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Dr Reddy's Laboratories launches generic Sugammadex injection in the United StatesDr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effec...
- MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipelineSun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...
- Losing weight fast on GLP-1 drugs? Your hair could be the next thing to goDermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen efflu...
- Lupin launches generic Sugammadex injection in USLupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Admini...
- Gland Pharma gets USFDA nod for generic sugammadex injectionGland Pharma secured USFDA approval for its sugammadex injection generic version. This drug reverses muscle relaxant effects used during su...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...
- Dr Reddy’s aims to resume semaglutide supply by November after API fixDr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and pla...
Load More
